oa SA Pharmaceutical Journal - New drug focus

Volume 73, Issue 7
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Extracted from text ... SA Pharmaceutical Journal - August 2006 48 DRUG INFO APIDRA(tm) injection - A new rapid-acting insulin analogue Approved indication APIDRA(tm) contains the insulin analogue, insulin glulisine. It is indicated for the treatment of diabetes mellitus, where insulin therapy is required. Insulin glulisine has a rapid onset of action and a shorter duration of action than human soluble insulin, when given subcutaneously. It is normally used in regimens that include a longeracting insulin or a basal insulin analogue. Mode of action Insulin glulisine is a rapid-acting, parenteral blood glucose lowering agent. Insulin glulisine is produced by recombinant DNA technology using Escherichia ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error